National Unit for Full-Stage Development
of Immune Cell Gene Therapy (NDIT)

NDIT Supports the Full-stage Development of Immune Cell Gene Therapies for Solid Tumors
by Accelerating the Translation of Discovery into Clinical Application

OUR VISION

Bringing Hope for Overcoming Cancer, Enhancing Quality of Life

OUR GOAL

Validating the Safety and Efficacy(or Technology Concept) of Immune Cell Gene Therapies for Solid Tumors through Clinical Research

• 
  Developing Next-Generation Immune Cell Therapy Platforms for Solid Tumors
  Core technologies for CAR-T, TCR-T, and TIL therapies
• 
  Developing Precision Medicine Technologies based on Cancer-Specific Neoantigens
  Personalized therapeutic technologies to overcome heterogeneity in solid tumors
• 
  Establishing Clinically Applicable CMC/QC Systems
  Manufacturing processes and quality control standards for clinical-grade cell and vector production.
• 
  Focus on Early-stage Clinical Research
  Evaluating safety, PK/PD, toxicology, and antitumor efficacy to generate clinical evidence
• 
  Building an Advanced Regenerative Medicine Ecosystem for Solid Tumors
  Establishing a full-stage platform connecting basic research, preclinical development, manufacturing, and clinical application.